Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petar Lenert

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
European Journal of Immunology|June 23, 2006
Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus miceRachel Brummel, Tara L Roberts, Katryn J Stacey, et al.
DNA and Cell Biology|November 13, 2003
Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cellsPetar Lenert, Wendy Rasmussen, Robert F Ashman, et al.
International Immunology|March 5, 2005
Sequence requirements for oligodeoxyribonucleotide inhibitory activityRobert F Ashman, J Adam Goeken, Jennifer Drahos, et al.
Seminars in Arthritis and Rheumatism|March 10, 2018
Hydralazine-associated vasculitis: Overlapping features of drug-induced lupus and vasculitisBharat Kumar, Jennifer Strouse, Melissa Swee, et al.
International Immunology|March 12, 2011
Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 bindingRobert F Ashman, J Adam Goeken, Eicke Latz, et al.
Journal of Clinical Immunology|March 3, 2005
TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 productionPetar Lenert, Rachel Brummel, Elizabeth H Field, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2018
Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities?Umang Swami, Petar Lenert, Muhammad Furqan, et al.
Antisense & Nucleic Acid Drug Development|September 5, 2003
Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cellsPetar Lenert, Ae-Kyung Yi, Arthur M Krieg, et al.
European Journal of Immunology|September 3, 2010
FcγRIIB regulation of BCR/TLR-dependent autoreactive B-cell responsesAna M Avalos, Melissa B Uccellini, Petar Lenert, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|October 16, 2020
Atypical Large Vessel Vasculitis Presenting With Cholestatic Liver Abnormalities: Case-Based ReviewSameet Sangha, Aleksander Lenert, Salma Dawoud, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
European Journal of Immunology|June 23, 2006
Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus miceRachel Brummel, Tara L Roberts, Katryn J Stacey, et al.
DNA and Cell Biology|November 13, 2003
Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cellsPetar Lenert, Wendy Rasmussen, Robert F Ashman, et al.
International Immunology|March 5, 2005
Sequence requirements for oligodeoxyribonucleotide inhibitory activityRobert F Ashman, J Adam Goeken, Jennifer Drahos, et al.
Seminars in Arthritis and Rheumatism|March 10, 2018
Hydralazine-associated vasculitis: Overlapping features of drug-induced lupus and vasculitisBharat Kumar, Jennifer Strouse, Melissa Swee, et al.
International Immunology|March 12, 2011
Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 bindingRobert F Ashman, J Adam Goeken, Eicke Latz, et al.
Journal of Clinical Immunology|March 3, 2005
TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 productionPetar Lenert, Rachel Brummel, Elizabeth H Field, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2018
Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities?Umang Swami, Petar Lenert, Muhammad Furqan, et al.
Antisense & Nucleic Acid Drug Development|September 5, 2003
Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cellsPetar Lenert, Ae-Kyung Yi, Arthur M Krieg, et al.
European Journal of Immunology|September 3, 2010
FcγRIIB regulation of BCR/TLR-dependent autoreactive B-cell responsesAna M Avalos, Melissa B Uccellini, Petar Lenert, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|October 16, 2020
Atypical Large Vessel Vasculitis Presenting With Cholestatic Liver Abnormalities: Case-Based ReviewSameet Sangha, Aleksander Lenert, Salma Dawoud, et al.
Pageof 4